Compare NMRA & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMRA | EIC |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.4M | 293.8M |
| IPO Year | 2023 | 2019 |
| Metric | NMRA | EIC |
|---|---|---|
| Price | $1.72 | $11.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | $8.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 994.8K | 286.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 13.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $59,262,402.00 |
| Revenue This Year | N/A | $37.84 |
| Revenue Next Year | N/A | $23.33 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | ★ 44.30 |
| 52 Week Low | $0.61 | $10.81 |
| 52 Week High | $11.57 | $16.39 |
| Indicator | NMRA | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 32.32 | 51.05 |
| Support Level | $1.68 | $11.00 |
| Resistance Level | $2.36 | $11.44 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.04 | 0.08 |
| Stochastic Oscillator | 5.90 | 87.84 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.